Clinical trials: Degenerative Neurologic Disease
Parkinson Disease
Robotic Walking Device to Improve Mobility in Parkinson's Disease
This Phase II randomized controlled trial proposes to examine the impact of long-term use of a novel light-weight and wearable assistive robotic device, called the Honda Walking Assist (HWA) device, to improve mobility in the…
- Trial name
- NCT03751371
- Testing
- Training with HWA device, Usual Care
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University
Parkinson's Disease
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy.
- Trial name
- NCT00399477
- Testing
- rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa
- Volunteers
- 200 people
- Sponsor
- Teva Neuroscience, Inc.
Neurofibromatosis Type 2, Severe Profound Sensorineural Hearing Loss
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
The Nucleus 24 Auditory Brainstem Implant (ABI) is the only FDA approved device for restoration of meaningful hearing in Neurofibromatosis Type 2 (NF2) patients.
- Trial name
- NCT02589912
- Testing
- Nucleus Profile ABI541 Auditory Brainstem Implant
- Where
- United States
- Sponsor
- Massachusetts Eye and Ear Infirmary
Alzheimer Disease
A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease
Potentially inappropriate prescribing includes the use of medications that may no longer be necessary or that may increase the risk of harm.
- Trial name
- D-PRESCRIBE-AD (NCT05147428)
- Testing
- Educational Materials
- Where
- United States
- Volunteers
- 14,442 people
- Sponsor
- University of Massachusetts, Worcester
Parkinson Disease
Low Intensity Focused Ultrasound for Parkinson's Disease
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with parkinson's Disease
- Trial name
- NCT06763692
- Testing
- LIFU Neuromodulation
- Volunteers
- 15 people
- Sponsor
- Ali Rezai
Parkinson's Disease
Clinical, Molecular and Metabolic Characteristics of Parkinson's Disease (PD) Patients With Parkin Mutation
Parkinson's disease is a frequent neurodegenerative disorder. Genetic forms of the disease have been recently identified. The monogenic form due to parkin mutation is responsible for many familial cases and sporadic forms.
- Trial name
- NCT00169364
- Testing
- positron emission tomography
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Alzheimer's Disease
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)
The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories…
- Trial name
- NCT02079909
- Testing
- T-817MA-H, T-817MA-L
- Where
- 50 sites in United States
- Volunteers
- 482 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Parkinson Disease
DBS Virtual Learning Experience
The success of Deep Brain Stimulation (DBS) is more correlated to fulfillment of patients' expectations, than merely improvement of motor status1.
- Trial name
- NCT06436313
- Testing
- Educational Sessions
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of Toronto
Parkinson Disease, Physical Disability
Effectiveness of a Program With Aquatic Therapy in Patients With Parkinson's Disease Clinical Trial
The aim of this study is to determine the effect of an aquatic Ai Chi training program on the perception of pain, the maintenance of balance and the functional independence of patients with Parkinson's disease.
- Trial name
- NCT04169620
- Testing
- aquatic Ai Chi, control
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Universidad de Almeria
Parkinson s Disease
The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease
This study aimed to evaluate the clinical efficacy and safety of temporal interference stimulation (TIS) targeting different targets in patients with Parkinson's disease (PD), and to investigate the associated neurophysiological…
- Trial name
- NCT07572903
- Testing
- Temporal Interference Stimulation
- Where
- China
- Volunteers
- 96 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
At Risk for AD-dementia, With Subjective Cognitive Decline, At Risk for Cognitive Decline
High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults
The goal of this clinical trial is to learn whether a 12-week high-velocity resistance training program can improve brain blood flow and thinking skills in adults ages 60 to 79 who are at higher risk for Alzheimer's disease and…
- Trial name
- NCT07444554
- Testing
- High-Velocity Resistance Training
- Volunteers
- 60 people
- Sponsor
- University of Illinois Chicago
Neurofibromatosis Type 2, Vestibular Schwannoma
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with…
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
- Trial name
- INTUITT-NF2 (NCT04374305)
- Testing
- Brigatinib, Neratinib, Retifanlimab
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Scott R. Plotkin, MD, PhD
Neurofibromatosis Type 1
Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)
The purpose of this study is to determine the incidence and clinical history of neurofibromatosis type 1-related spinal abnormalities.
- Trial name
- Spine (NCT00844129)
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of Utah
Parkinson Disease
The Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Depression in PD
This study is a double blind comparative study examining the effectiveness of the transcutaneous auricular vagus nerve stimulation treatment on Parkinson's disease patients with depression.
- Trial name
- PD-D-taVNS (NCT07679529)
- Testing
- Active Transcutaneous auricular vagus nerve stimulation
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Parkinson's Disease, Deep Brain Stimulation
Predicting Cognition After DBS for Parkinson's Disease
The aim of the study is to improve estimation of cognitive outcome after STN-DBS in PD in order to avoid risk factors by optimizing peri- and intraoperative management personalize therapeutic strategies for optimal long-term…
- Conditions
- Parkinson's Disease, Deep Brain Stimulation, Postoperativeneurocognitive Deficit, Postoperative Delirium
- Trial name
- NCT03982953
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Charite University, Berlin, Germany
Alzheimer Disease
the Safety and the Efficacy Evaluation of Allogenic Adipose MSC-Exos in Patients With Alzheimer's Disease
Evaluate the Safety and Efficacy of Exosomes Derived from Allogenic Adipose Mesenchymal Stem Cells（MSCs-Exos）in Subjects with Alzheimer's disease.
- Trial name
- NCT04388982
- Testing
- low dosage MSCs-Exos administrated for nasal drip, mild dosage MSCs-Exos administrated for nasal drip, high dosage MSCs-Exos administrated for nasal drip
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Ruijin Hospital
Alzheimer Disease
Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine
Current therapeutic approaches for the treatment of neurodegenerative diseases like Alzheimer disease (AD) offer limited and often transient symptomatic benefits to patients but do not mitigate the insidious loss of neuronal…
- Trial name
- NCT01696123
- Testing
- MLC601
- Where
- Iran
- Volunteers
- 125 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Spinal Muscular Atrophy
A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA
An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy with EXG001-307 in SMA1 patients ,who joined the parent study (EXG001-307-102)
- Trial name
- NCT06588803
- Testing
- No intervention, only for observational studies
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Parkinson Disease, Essential Tremor
Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings
Parkinson's disease and essential tremor are chronic movement disorders for which there is no cure. When medication is no longer effective, deep brain stimulation (DBS) is recommended.
- Trial name
- CHANNEL DBS (NCT04658641)
- Testing
- Boston Scientific: Study tool computer
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- KU Leuven
Amyotrophic Lateral Sclerosis
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)
The primary objective is to evaluate the long-term safety and tolerability of BIIB078 in participants with chromosome 9 open reading frame 72-amyotrophic lateral sclerosis (C9ORF72-ALS).
- Trial name
- NCT04288856
- Testing
- BIIB078
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 75 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.